Importantly, biologics for the treatment of moderate to severe HS, including secukinumab (IL-17A inhibitor) and adalimumab (anti-TNFα), effectively hamper inflammatory cascades that contribute to immune cell and elevated cytokine level activity in HS lesions [33,70]. The gene discussed is IL17A; the disease is histiocytic sarcoma.